{
    "2021-05-09": [
        [
            {
                "time": "",
                "original_text": "继投下4个“恒瑞”，大半个“上海医药”后，高瓴又来钱了！1160亿又会买谁？大药企、CRO、投资机构争夺战要开始了？",
                "features": {
                    "keywords": [
                        "高瓴",
                        "恒瑞",
                        "上海医药",
                        "1160亿",
                        "大药企",
                        "CRO",
                        "投资机构"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "下周解禁市值超1700亿，药明康德解禁超900亿元 解禁",
                "features": {
                    "keywords": [
                        "解禁",
                        "市值",
                        "药明康德",
                        "1700亿",
                        "900亿"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}